On Might 27, Barclays analyst Andrew Mok CFA maintained an Equal Weight ranking on Surgical procedure Companions, Inc. (NASDAQ:SGRY) and diminished the value goal to $24 from $25.
The ranking replace got here after Surgical procedure Companions, Inc. (NASDAQ:SGRY) reported combined fiscal Q1 2025 outcomes on Might 12. The analyst informed traders in a analysis replace that whereas the corporate’s efficiency for the quarter confirmed efficient doctor recruitment and robust demand, elements reminiscent of rising unit prices and slower pricing development demand a cautious method.
A surgeon sporting gloves and a masks, performing a process in a well-equipped surgical facility.
Surgical procedure Companions, Inc. (NASDAQ:SGRY) added round 150 new physicians to its amenities in fiscal Q1 2025, most of whom administration expects to change into companions finally. Income for the quarter rose 8.2%, whereas adjusted EBITDA grew round 7%, supported by sturdy natural outcomes. This included sturdy demand and same-facility income development of greater than 5%.
Nonetheless, the corporate missed on earnings expectations in its fiscal Q1 2025 outcomes, with reported EPS of $0.04 falling beneath the anticipated $0.08. Web loss attributed to the corporate within the quarter got here as much as $37.7 million. These contrasting developments led the analyst to slash the value goal for Surgical procedure Companions, Inc. (NASDAQ:SGRY).
Surgical procedure Companions, Inc. (NASDAQ:SGRY) is a healthcare providers firm that gives surgical and associated ancillary care options. Its operations are divided into the Surgical Facility Providers, Ancillary Providers, and Optical Providers enterprise segments.
Whereas we acknowledge the potential of SGRY as an funding, our conviction lies within the perception that some AI shares maintain higher promise for delivering larger returns and have restricted draw back danger. If you’re searching for an AI inventory that’s extra promising than SGRY and that has 100x upside potential, take a look at our report concerning the least expensive AI inventory.
READ NEXT: 10 Finest Debt Free IT Penny Shares To Purchase and 10 Unstoppable Shares That Might Double Your Cash.
Disclosure: None.
